Efficient vaccination against viral agents requires a strong T-cell-mediated immune response to clear viral-infected cells. Optimal vaccination can be achieved by administration of recombinant viral vectors encoding phatogen antigens. Adenoviral vectors have attracted considerable attention as potential viral vectors for genetic vaccination owing to their favorable safety profile and potent transduction efficiency following intramuscular injection. However, the neutralizing antibody response against adenoviral capsid proteins following adenoviral vectors injection limits the success of vaccination protocols based on multiple administrations of the same adenoviral serotype. In this work, we describe efficient immunization of rhesus macaques, the preferred model for preclinical assessment, with an HCV candidate vaccine by heterologous priming-boosting with adenoviral vectors based on different serotypes. The induced responses are broad and show significant cross-strain reactivity. Boosting can be delayed for over 2 years after priming, indicating that there is long-term maintenance of resting memory cells.
Introduction
Genetic vaccines based on replication-defective adenoviruses have been shown to elicit a strong and longlasting T-cell response against a number of viral antigens [1] [2] [3] [4] and are currently used for vaccine trials in humans (for a review, see Rocha et al. 5 and Tatsis and Ertl 6 ). The most commonly used adenoviral vectors are derived from the subgroup C member serotypes 2 and 5. 1, 7 The closely related serotype 6 has also been successfully used for HCV and HIV vaccination in rodents and rhesus macaques 1 (Capone et al. 8 ). Additional vectors derived from chimpanzee adenoviruses or from the rare serotypes 34 and 35 (group B) and 24 (group D) have been shown to be immunogenic, although at a lower level than human group C-based vectors. 1, [9] [10] [11] [12] One of the shortcomings of adenoviral vectors for vaccine applications is the limited efficacy in boosting immune responses after repeated administrations. This is due to strong antivector neutralizing antibodies, which are readily induced even after a single injection, thereby preventing target cell infection upon re-dosing of the same vector.
An alternative approach to the repeated injection of group C human adenoviral vectors is to employ a heterologous prime/boost immunization regimen based on the use of different vectors, including plasmid DNA as well as vaccine vectors derived from different viruses. This strategy proved to be extremely effective at increasing the overall immune response as compared to the use of a single vector. 1, 5, 13 So far, few data are available on adenoviral vaccines in human or primates, although adenovirus-based vectors show a greater efficiency in rodents. 7 In this work, we have tested the potency of a heterologous prime/boost strategy based on a combination of human group C Ad6 or Ad5 vectors with the rare human serotype belonging to subgroup D Ad24, or two chimpanzee adenoviruses, C32 and C33, that have low seroprevalence in the human population. Rhesus macaques immunized by heterologous prime/boost with an HCV vector based on different, non-crossreactive adenovirus serotypes showed a strong and multispecific cellular-mediated immune response far superior to those observed after homologous boost. Efficient boosting with heterologous vectors was observed even after 2 years from the primary set of injections. The present results support the use of multiple adenoviral vectors derived from different serotypes as a more efficient approach for genetic vaccination.
Results

Prevalence of neutralizing antibodies against human and chimpanzee vaccine vectors
Neutralization assays were carried out in order to evaluate the prevalence, in human sera, of neutralizing antibodies against human Ad5 and Ad6 and the chimpanzee adenoviruses C32 and C33. The assay evaluated the effects of serum preincubation on the ability of CVs carrying the gene for secreted alkaline phosphatase (SEAP) to transduce human 293 cells. The neutralization titer is defined as the dilution of serum, giving a 50% reduction of the SEAP activity observed in the positive control with the virus alone. 14 A panel of 100 human sera was tested in parallel for human and chimp Ads neutralization activity. The result provided in Table 1 indicates a very low prevalence, in human sera, of neutralizing antibodies directed against vector derived from chimpanzee adenoviruses. Only four sera showed a titer over the threshold of 200 on C32 vector, and none of them on C33. As expected, human Ad5 showed a high seroprevalence with 33% of tested sera over 200, whereas Ad6 with only 12% of sera with high titer demonstrated a better seroprevalence profile. On the contrary, the panel of chimp sera examined showed a very high prevalence of anti-chimp adenovirus immunity (not shown). These findings confirm that as expected, vectors based on chimp Ads have a very little chance to be neutralized in humans. 15 Immunological potency of adenoviral vectors in mice Dose/response studies were conducted in mice to assess the immunological potency of vectors expressing the non-structural region of HCV (NS) based on human Ad5, Ad6 and Ad24, and on chimpanzee C32 and 33.
HCV-specific cellular-mediated immune response was measured, 3 weeks after intramuscular injection of increasing doses of each vector, by interferon-g (IFN-g) ELISPOT on splenocytes from C57/Bl6 mice that were stimulated with the H2K b -restricted peptide 1480 (aminoacid sequence GAVQNEVTL), which was previously mapped as a CD8 epitope in this mouse strain. Human group C-derived MRKAd5NSmut and MRKAd6NSmut vectors showed comparable immunological potency and gave similar ELISPOT counts at the 10 7 and 10 8 viral particle (vp) doses (Figure 1a and b) , whereas both C32NSmut and C33NSmut had a lower potency, and significant T-cell responses were observed at the 10 8 vp (Figure 1c and d) . Finally, the Ad24-based vector was significantly less immunogenic as it was able to induce a measurable response only at the highest dose of 10 9 vp (Figure 1e ).
Heterologus prime/boost immunization of rhesus macaques
Rhesus macaques were immunized with 10 10 vp of MRKAd6 NSmut. The immunization schedule consisted of two priming injections at T ¼ 0 and 4 weeks and a boosting injection at T ¼ 24 weeks (white arrows in Figure 2b) .
Injection of the NS-encoding virus elicited potent NSspecific T-cell responses already after the first priming injection with an average value in the three monkeys of 2045 IFN-g-secreting spot-forming cells (SFC) per 10 6 peripheral blood mononuclear cells (PBMCs) (Figure 2b ). The response did not improve after re-dosing of the vector and then progressively declined to an average of 864 SFC/10 6 PBMCs at week 24. Homologous boosting at T ¼ 24 was ineffective and the magnitude of the response did not improve over the one obtained after the priming (Figure 2) .
The lack of an efficient recall response after boosting at week 24 could be due to high titers of antivector neutralizing antibodies that were readily induced already after the first administration ( Table 2) . Neutralizing titers remained very high at the time of the boosting and for almost 1 year (week 51) after initiation of the study (Table 2) . We have previously shown that neutralization titers as low as 300 completely abolish immune response after homologous vector administration (Capone et al. 8 ). We reasoned therefore that administration of adenoviral vectors of a different serotype encoding the same antigen could overcome the neutralization of the antigroup C adenovirus antibodies and would result in efficient boosting of T-cell responses against the HCV NS antigens. Therefore, animals were injected with 10 10 vp of the C32NSmut vector. Neutralizing titers against this chimpanzee vector were below the limits of detection at the time of injection (week 51) in all of the three monkeys ( Table 2) .
Following heterologous boosting, antigen-specific T-cell responses increased to much higher levels than those observed after priming or homologous boosting (Figure 2a ) and the average number of specific lymphocytes was 4924 SFC/10 6 PBMCs at week 54 versus 2045 SFC/10 6 PBMCs at week 4 ( Figure 2b ). To determine the subtype of the T-cell response, peptide-stimulated PBMCs were analyzed by IFN-g intracellular assay and surface staining for CD3/CD8 or CD3/CD4 markers followed by FACS analysis.
As already reported for Ad5gag, 1 the response was mainly of CD8+ subtype (Table 3) .
Increased breadth of anti-HCV CMI response after boosting with heterologous adenoviral vectors
Given the large heterogeneity of the human HLA class I and class II alleles and the extreme variability of the HCV genome, efficacy of anti-HCV cell-mediated immune responses is likely to depend on the level of polyspecificity. Table 4 shows the extent of CMI against different regions of the NS polyprotein in MRKAd6Nsmut-immunized animals measured by IFN-g ELISPOT at different time points. The first MRKAd6NSmut injection elicited a polyspecific response directed against at least two peptide pools (00D116) and up to a maximum of 5/6 peptide pools (00D065). The broadest response was achieved following heterologous boosting with one monkey displaying T-cell reactivity against all NS pools and the other two animals showing efficient response to five peptide pools (Table 4 ). Po0.05 Table 2 Neutralization titers against Ad6 and C32 measured in sera of rhesus immunized as described in the legend to Figure HCV is a highly heterogeneous virus consisting of six different major genotypes and a large number of subtypes. We wished to test the potential of our HCV vaccine candidates based on the genotype/subtype 1b to induce a T-cell response capable of recognizing the most divergent genotype 3a (23% amino-acid diversity). For this purpose, IFN-g ELISPOT analysis was performed on PBMCs from rhesus macaques immunized with MRKAd6NSmut and boosted with C32NSmut. T-cell reactivity was measured at T ¼ 4 weeks post-priming and T ¼ 54 weeks (3 weeks after heterologous boosting) using two sets of overlapping peptides reproducing the NS 1b vaccine sequence and a representative genotype 3a sequence (Table 5 ). Although not all 3a peptide pools were tested for each analyzed monkey, we show that, already after priming, crossreactivity between genotypes Table 4 ) or DMSO as negative control. CD3+ lymphocytes were stained for CD8 or CD4 and IFN-g production.
Values are expressed as percentage of IFN-g-producing CD3+CD4+/ CD3+ or CD3+CD8+/CD3+. Bold characters are positive responses. Cross-reactivity in Interferon-g ELISPOT of NS-specific T cells to peptide pools designed on genotypes 1b and 3a in monkeys immunized with Ad5NSmut and C32NSmut as described in the legend to Figure 1 Efficient immunization of rhesus macaques E Fattori et al 1b and 3a was observed in at least one animal (00D159, NS5a). As already shown, following heterologous boosting, the response against the 1b NS region was highly polyspecific with 2/3 animals (00D116 and 00D0159), showing a significant reactivity against all five peptide pools and one (00D065) against all six. In all three monkeys, there was a good degree of crossreactivity against the 3a antigens. Crossreactivity was limited to a single pool (NS5a) in 00D065, whereas in 00D116 and 00D159, three regions were crossreactive (NS3p, NS3h and NS5b-2 in 00D116; and NS3p, NS5a and NS5b-1 in 00D159). Owing to the small number of animals and peptide pool analyzed, a careful statistical analysis between the extent of crossreactivity after priming and after heterologous boosting is not possible. Nevertheless, the demonstration that T-cell response can efficiently crossreact against two of the most common and genetically distant viral strains is an indication of the possible broad protection of this vaccine setting.
Induction of potent anamnestic responses by late heterologous boosting
To monitor the efficiency of CMI recalling by boosting with alternate serotypes vectors at later time points, we re-injected rhesus macaques previously immunized with 10 10 or 10 8 vp of the MRKAd6NS vector (Capone et al. The magnitude of immune response after heterologous boosting was higher than after both post-Ad6 prime and homologous boosting, reaching in some animals (113Q, 138T) levels close to 10 000 SFC/10 6 PBMCs, equivalent to 1% of total PBCMs (Figure 3 , groups A and C).
Discussion
Replication-defective adenoviruses (FG Adeno) are safe and potent viral vectors for genetic vaccine delivery. In addition, Ad E1 stably transfected production cell lines are available that can support the production of high titer FG vectors based on group C human adenoviruses with no risk of recombination and reversal to the wildtype replication competent virus. 16 As a result of these features, a number of clinical studies are being conducted to assess safety and immunogenicity, in humans, of candidate vaccines against viral diseases and cancer. 17, 18 However, boosting with adenovirus vectors is inefficient in the context of homologous prime/boost modality of immunization owing to the rapid induction of antivector neutralizing antibodies. Although different heterologous prime/boost regimens based on combination of DNA and pox virus vectors 7 or VSV vectors based on different serotypes 19 have been shown to improve T-cell responses in rodents and non-human primates, it is still unclear if these will be sufficiently immunogenic in humans. 7 We cannot, however, judge the relative efficiency of the adeno-based or the above-mentioned strategies, as a direct comparison in the same experimental setting was not performed.
A recent study has shown efficient T-cell response to HIV gag in rhesus, using triple immunization vaccine based on injection of high doses (10 12 vp) of simian (C6 and C7) and human (Ad5) adenoviruses. 15 In this vaccination context, boosting efficiency was demonstrated 1 year after primary immunization.
In this work, we describe the construction and use of multiple adenoviral vectors based on different, noncross-reacting serotypes that direct expression of the HCV NS polyprotein fragment.
Heterologous boosting of rhesus macaques primed with group C human adenoviral vectors improved the magnitude of HCV T-cell responses by -two to threefold, with levels of circulating virus-specific T cells with effector function reaching up to 0.9% of total PBMCs. In the case of HCV vaccination, this massive expansion of T lymphocytes far exceeds what has been observed in acute/resolving infected humans using the same assays and reagents (Folgori et al. 20 ). We have also verified the efficacy of heterologous boosting using C33NSmut or Ad24NSmut when low (10 8 vp) doses of MRKAd5NSmut or MRKAd6NSmut were administered as primary immunization. Studies in Ad5 pre-exposed non-human primates showed that a 100-fold increase in dose is needed to achieve frequencies of transgene product-specific CD8+ T cells comparable to those obtained in animals that had not been preexposed. 21 The 10 8 dose in rhesus would therefore mimic the immunization potency obtained by administering the 10 10 vp doses in human with neutralizing anti-Ad5 antibodies. No differences were observed in the number of antigen-specific IFN-g -producing cells post-heterologous boosting between groups primed with the low or the high dose of MRKAd6NSmut or MRKAd5NSmut. Also, boosting with the stronger immunogen C33NSmut or the weaker Ad24NSmut yielded equivalent CMI, showing that in the context of sequential injections of heterologous adenoviral vectors, the relative potency of the single viruses is not a strong predictor of the immunization efficiency.
Recent studies during acute infection in humans showed that multispecific T-cell responses directed against both structural and non-structural antigens are more frequent and are significantly stronger in patients who cleared infection than in those who did not. 22 Consistently, data obtained in the chimpanzee infection model support the correlation between strength and breadth of antiviral CMI and resolution of infection. 23 We have shown that after heterologous boosting in rhesus macaques, the breadth of anti-HCV CMI increases significantly and targets all tested NS proteins. Moreover, the response elicited by the adeno-vectored genotype 1b vaccine was crossreactive with peptides derived from the Efficient immunization of rhesus macaques E Fattori et al highly divergent genotype 3a, which has 23% amino-acid diversity. This finding is of particular relevance, given the large heterogeneity of viral isolates, and holds promise for the present candidate and vaccination strategy to provide cross-genotype protection against acute and chronic disease.
Materials and methods
Adenoviral vector construction
The construction of the HCV NS expression cassette and the insertion into Ad6 vector generating the ). Wild-type chimp adenoviruses C32 and C33 were purchased from ATCC (ATCC accession numbers: C32, VR-592; C33, VR-593; Esoterix Inc., Austin, TX, USA) and propagated using the human E1-expressing cell line PER.C6t or 293.
All wild-type CV stocks were cloned by infecting 293 cells seeded in 96-well plates, after the first passage of amplification. The virus cloning was performed by limiting dilution of the cell lysate obtained at the first passage of the virus amplification. Then, five isolated clones were picked up and serially propagated. After 3-4 serial passages of amplification, a large-scale preparation 
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of adenovirus was performed on cells planted on five two-layer cell-factories (NUNC). Purified viral particles were obtained from cell lysate by two ultracentrifugation steps on cesium chloride density gradients.
Construction of DE1 chimp adenoviral vectors
Genomic viral DNA was cloned into a standard plasmid vector by homologous recombination with a shuttle vector (pARS C32) containing both left and right ends of C32 genome. The left end includes ITR, packaging signal and pIX transcription unit and contains deletion of the entire E1 region. The right end of viral genome cloned into pARS C32 includes the right ITR and part of the E4 region.
In order to construct DE1 vectors based on chimp adenovirus, the shuttle vector pARS C32 was linearized with AscI present between the pIX region and the right end, and co-transformed into Escherichia coli strain BJ5183 with C33 and C32 purified viral DNA. Homologous recombination between DNA sequences from pIX genes and right ITR present at the ends of linearized pARS C32 and viral genomic DNA allowed its insertion in the plasmid vector, deleting at the same time the E1 region.
Expression cassettes based on human cytomegalovirus promoter and bovine growth hormone polyadenylation signal were constructed to express SEAP and HCV NS genes and were inserted into C32 and C33 vectors by replacing the E1 region. All the expression cassettes were inserted into the single SnaBI site of pARS C32 vector to be transferred by homologous recombination into the DE1 pre-adeno plasmids.
Rescue and amplification of DE1 vectors 5 Â 10 6 PER.C6 cells planted on 6 cm cell culture dishes were transfected with 10 mg of cloned viral vector released from plasmid sequences by endonuclease digestion. DNA transfection was performed using Lipofectamine (Invitrogen, Carlsbad, CA, USA).
Transfected cells and culture medium were collected 5-10 days post-transfection and lysed by freeze-thaw. Rescued vectors were then amplified by serial passaging on 293 or PerC6 cells. A large-scale amplification was performed by infecting cells planted on 5-10 cellfactories (NUNC Inc., Rochester, NY, USA) on a total of 1-2 Â 10 9 cells. A purified vector preparation was obtained on cesium chloride gradient by two ultracentrifuge runs, dialyzed against buffer A195 and quantified by genome quantification assay as described. 24 Expression of HCV NS proteins was tested by infecting HeLa cells with different multiplicity of infections and detecting NS3, NS5a and NS5b proteins as described. 25 
Neutralization assay
The neutralizing titers against the adenoviruses used in this study were evaluated as described previously. 26 Animals C57/Bl6 mice were purchased at Charles River (Como, Italy).
Rhesus macaques (Macaca mulatta) were housed at NIRC (New Iberia Research Center, Louisiana, USA). Housing, handling and performance of the experiments all followed the legal requirements.
Peripheral blood mononuclear cells and serum preparation
Blood samples were collected from the femoral vein using aseptic techniques: vacutainer blood collection systems (Becton Dickinson, Vacutainer systems) were used. Peripheral blood mononuclear cells from EDTAtreated peripheral blood were isolated by lymphocyte separation medium density gradient centrifugation (Organon Teknika). Cells at the interface were collected and washed twice in RPMI-1640 medium. To lyse erythrocytes, the cell pellets were resuspended in 5 ml of erythrocyte shock medium (ACK lysing buffer, Gibco-BRL, Grand Island, NY, USA, custom made), and left at room temperature for 5-10 min. Peripheral blood mononuclear cells were washed once, resuspended in R10 medium (RPMI medium 1640, supplemented with 10 mM HEPES buffer, 2 mM L-glutamine, 50 U/ml of penicillin and 50 mg/ml of streptomycin, 50 mM 2-mercaptoethanol (all GibcoBRL) and 10% fetal bovine serum (HyClone, Logan, UT, USA)) and then used in the assays.
For serum preparation, untreated blood samples stood were kept at room temperature for at least 30 min, then the clotted blood was centrifuged for 10 min (1300 g), and serum was removed and immediately stored frozen in aliquots at À201C.
Peptides for T-cell assays
The peptide sequence spanning the NS3-NS5B region reproduced the amino-acid sequence of the HCV BK 1b or 3a strains.
Peptides were purchased from Bio-Synthesis Inc., Lewisville, TX, USA. All peptides were synthesized with free N-terminal amine and free C-terminal carboxylate and were purified by preparative high-performance liquid chromatography. The peptides, 15 amino acids (aa) in length and overlapping by 11 aa (NS3-NS5b), were reconstituted in 100% dimethylsulphoxide (DMSO) at 40 mg/ml (NS3-NS5b) and mixed in pools so that each peptide is equally represented in the mixture. To facilitate the analysis, the 491 NS3-NS5b peptides were combined in seven pools covering NS3 protease (NS3p), NS3 helicase (NS3h), NS4, NS5A and NS5B (split in two pools NS5B-I and NS5B-II).
Interferon-g ELISPOT
Interferon-g ELISPOT assay with rhesus PBMC was performed as follows: PBMCs were plated in duplicate at two different cell concentrations/well (400 000 and 200 000). HCV peptide pools, DMSO and concavalin A (ConA) (Sigma-Aldrich, C 2010) were used, respectively, as antigen, negative and positive control. Interferon-g spots were revealed using biotinylated rabbit anti-monkey IFN-g monoclonal antibody (U-Cytech) diluted 1:100. Spots were quantified by an automated ELISPOT reader system (ELR03 AID ELISPOT Scientific).
The ELISPOT response was considered positive when all of the following conditions were met: IFN-g production present in Con-A-stimulated wells; the number of specific spots/million PBMC to at least one HCV peptide pool was greater than 55; the number of spots seen in positive wells was three times the number detected in the mock control wells (DMSO) and in serial dilutions of PBMC, the responses were titratable.
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Interferon-g ELISPOT assay on mouse splenocytes was performed as described. 27 Spleens were aseptically removed from euthanized mice and ground onto a stainless steel mesh. Cell suspension was diluted in a final volume of 4 ml R10 medium, debris were decanted for a few minutes, and then cells were centrifuged at 250 r.p.m. for 10 min at room temperature. Red blood cells were osmotically lysed by resuspending the cell pellet in 1 ml 0.1 Â PBS for 15 s and then adding to the cell suspension 1 ml 2 Â PBS for another 15 s. After adding 2 ml of 1 Â PBS cell, membranes were decanted for a few minutes and final splenocyte preparation was pelleted and resuspended in a final volume of 1 ml R10 medium. Then, ninety-six-well plates with PVDF membrane (Millipore MAIP 45) were coated overnight at 41C with 100 ml of a 1:400 PBS dilution of a purified rat anti-mouse IFN-g antibody (Pharmingen, San Diego, CA, USA). After washing, plates were blocked for 2 h at 371C with 200 ml/well of R10 medium. Antigen, in the form of single peptide, was added to the plates at a final concentration of 100 ng/well in 50 ml R10 medium. As positive control for IFN-g production, we used Con A (Sigma, St Louis, MO, USA) at a final concentration of 10 mg/ml. Splenocytes from each samples were added to the wells in duplicate at two different concentrations (2.5 Â 10 5 and 5 Â 10 5 cells/well). Plates were then left at 371C, 5% CO 2 overnight. After discarding the cells, a 1:250 dilution of biotin-conjugated rat antimouse IFN-g antibody (Pharmingen) was added to the plates and left overnight at 41C. Interferon-g spots were then detected by incubating plates with a 1:2500 dilution of a streptavidin-AP conjugate (Pharmingen) for 2 h at room temperature and by adding 50 ml of NBT/BCIP 1 Step (PIERCE). The reaction was stopped with deionized water and plates were air-dried. Spots were quantified by an automated ELISPOT reader system (ELR03 AID ELISPOT Scientific).
Interferon-g intracellular staining
10
6 rhesus PBMCs in 1 ml RPMI 10% FCS were incubated with a pool of peptides (5 mg/ml final concentration of each peptide) and anti-CD28 and anti-CD49d monoclonal antibodies (1 mg/ml each; Becton Dickinson catalog no. 550630 and 340976, respectively) at 371C and 5% CO 2 for 1 h before the addition of brefeldin A (1 mg/ml; Sigma-Aldrich catalog no. B-7651). Staphilococcal enterotoxin B (3 mg/ml; Sigma-Aldrich catalog no. S-4881) and DMSO were used as positive and negative controls, respectively. The cells were incubated for an additional 12 h at 371C in 5% CO 2 . Peripheral blood mononuclear cells were then washed and stained with surface antibodies CD3-APC (rhesus clone FN-18, custom conjugated), CD4-PE (clone L-200, Pharmingen catalog no. 550630) and CD8-PerCP (Beckton Dickinson catalog no. 345774) for 30 min at room temperature. After washing, PBMCs were fixed and permeabilized (Becton Dickinson, FACS Perm 2) and the IFN-g-FITC (Biosource catalog no. AHC4338) antibody was added. Cells were then washed and analyzed on an FACS-Calibur flow cytometer, using CellQuest software (Becton Dickinson); at least 30 000 CD8+ (or CD4+) and CD3+ gated events were acquired for each sample. A threshold for positive response was set at 0.1% IFN-g CD8+, CD4+ T cell/CD3+CD8+ or CD3+CD4+ T cells and three times the negative control.
